Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
6.73
+0.27 (4.18%)
At close: Mar 31, 2026, 4:00 PM EDT
6.78
+0.05 (0.74%)
After-hours: Mar 31, 2026, 4:10 PM EDT
Kyntra Bio Employees
Kyntra Bio had 34 employees as of December 31, 2025. The number of employees decreased by 191 or -84.89% compared to the previous year.
Employees
34
Change (1Y)
-191
Growth (1Y)
-84.89%
Revenue / Employee
$189,412
Profits / Employee
$5,395,647
Market Cap
27.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 34 | -191 | -84.89% |
| Dec 31, 2024 | 225 | -261 | -53.70% |
| Dec 31, 2023 | 486 | -106 | -17.91% |
| Dec 31, 2022 | 592 | 26 | 4.59% |
| Dec 31, 2021 | 566 | -33 | -5.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Boundless Bio | 28 |
| Longeveron | 25 |
| ABVC BioPharma | 19 |
| Quantum BioPharma | 17 |
| BriaCell Therapeutics | 16 |
| Serina Therapeutics | 13 |
| Exicure | 8 |
KYNB News
- 15 days ago - Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 22 days ago - Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - What's Going On With Kyntra Bio Stock Tuesday? - Benzinga
- 5 weeks ago - Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - GlobeNewsWire
- 6 weeks ago - Kyntra Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewsWire
- 5 months ago - FibroGen to Report Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire